The Russian Federation Health Ministry has granted approval to Theravance Biopharma’s Vibativ (telavancin) to treat Gram-positive complicated skin and soft tissue infections.

Vibativ is a once-daily, injectable lipoglycopeptide antibiotic with in-vitro potency and a dual mechanism of action against difficult-to-treat pathogens such as methicillin-resistance Staphylococcus aureus (MRSA).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

As part of a development and commercialisation agreement signed in 2012, the approval will allow R-Pharm to market and sell Theravance’s Vibativ in Russia. The antibiotic is expected to be commercially available in September.

“The antibiotic is expected to be commercially available in September.”

The clearance also results in a milestone payment to Theravance, including potential future contingent payments and a royalty on net sales.

Theravance Biopharma development and operations senior vice-president Frank Pasqualone said: “We are pleased that healthcare practitioners in Russia will now be able to add vibativ to their antibiotic choices, especially for those difficult-to-treat Gram-positive bacteria, such as MRSA, against which the drug has been shown to be an effective treatment.

“At the same time, this is another key achievement for Theravance Biopharma, highlighting the value of strategic collaborations with partners, such as R-Pharm, in our efforts to build the global brand and expand the commercial reach of vibativ into target markets outside the US.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

In the US, vibativ for injection is approved to treat hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus when alternative treatments are not suitable.

In addition, the drug is approved for treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of Gram-positive bacteria, including Staphylococcus aureus, both methicillin-susceptible (MSSA) and MRSA strains.

Outside the US, vibativ is currently being sold in Europe, Canada, Middle East, North Africa, Israel, and Russia.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact